Plasma sCD26 and sCD30 levels in cutaneous leishmaniasis

Acta Tropica

Volumn 109, Issue 1, 2009, Pages 61-63

  Jafari Shakib, R ^a   Shokrgozar, M A ^b   Nassiri Kashani, M ^c   Malakafzali, B ^c   Nikbin, B ^a   Khamesipour, A ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cutaneous leishmaniasis; sCD26; sCD30; Th1 Th2 response

Indexed keywords

CD30 ANTIGEN; DIPEPTIDYL PEPTIDASE IV;

COMPARATIVE STUDY; HEALTH STATUS; LEISHMANIASIS; PLASMA;

ADULT; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HUMAN CELL; HUMAN TISSUE; SKIN LEISHMANIASIS; STATISTICAL SIGNIFICANCE; TH1 CELL; TH2 CELL;

ADOLESCENT; ADULT; ANTIGENS, CD26; ANTIGENS, CD30; FEMALE; HUMANS; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; TH1 CELLS; TH2 CELLS; YOUNG ADULT;

EID: 56949105408     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2008.09.018     Document Type: Article

References (23)

1. Ajdary S., Alimohammadian M.H., Eslami M.B., Kemp K., and Kharazmi A. Comparison of immune profile of non-healing cutaneous leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect. Immun. 68 (2000) 1760-1764
2. Ajdary S., Riazi-Rad F., Jafari-Shakib R., and Mohebbali M. Soluble CD26/CD30 in visceral leishmaniasis: markers of disease activity. Clin. Exp. Immunol. 145 (2006) 44-47
3. Ajdary S., Jafari-Shakib R., Riazi-Rad F., and Khamesipour A. Soluble CD26 and CD30 levels in patients with anthroponotic cutaneous leishmaniasis. J. Infect. 55 (2007) 75-78
4. Annunziato F., Galli G., Cosmi L., Romagnani P., Manetti R., Maggi E., and Romagnani S. Molecules associated with human Th1 or Th2 cells. Eur. Cytokine Netw. 9 Suppl. 3 (1998) 12-16
5. Del Prete G., De Carli M., Almerigogna F., Daniel C.K., D'Elios M.M., Zancuoghi G., Vinante F., Pizzolo G., and Romagnani S. Preferential expression of CD30 by human CD4+ T cells producing Th2 type cytokines. FASEB J. 9 (1995) 81-86
6. Dowlati Y. Cutaneous leishmaniasis: clinical aspect. Clin. Dermatol. 14 (1996) 425-431
7. Fox D.A., Hussey R.E., Fitzgerald K.A., Acuto O., Poole C., Palley L., Daley J.F., Schlossman S.F., and Reinherz E.L. Ta1 A novel 105 KD human T cell activation antigen defined by a monoclonal antibody. J. Immunol. 133 (1984) 1250-1256
8. Habibi G.R., Khamesipour A., McMaster W.R., and Mahboudi F. Cytokine gene expression in healing and non-healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi-quantitative RT-PCR. Scand. J. Immunol. 54 (2001) 414-420
9. Hatam G.R., Hosseini S.M., and Ardehali S. Dermotropic isolates of Leishmania infantum in Iran. Trans. R. Soc. Trop. Med. Hyg. 91 (1997) 440
10. Herwaldt B.L. Leishmaniasis. Lancet 354 (1999) 1191-1199
11. Hoshimoto K., Ohta N., Ohkura T., and Inaba N. Changes in plasma soluble CD26 and CD30 during pregnancy: markers of Th1/Th2 balance?. Gynecol. Obstet. Invest. 50 (2000) 260-263
12. Jafari-Shakib R., Ajdary S., Amiri Z.M., Mohammadi A.M., Nourijelyani K., Mortazavi H., Shokrgozar M.A., Nikbin B., and Khamesipour A. CD26 expression on CD4+ T cells in patients with cutaneous leishmaniasis. Clin. Exp. Immunol. 153 (2008) 31-36
13. Katoh N., Hirano S., Suehiro M., Ikenaga K., Yamashita T., Sugawara N., and Yasuno H. Soluble CD30 is more relevant to disease activity of atopic dermatitis than soluble CD26. Clin. Exp. Immunol. 121 (2000) 187-192
14. Keane N.M., Price P., Lee S., Stone S.F., and French M.A. An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy. Clin. Exp. Immunol. 126 (2001) 111-116
15. Leonard C., Tormey V., Faul J., Burke C.M., and Poulter L.W. Allergen-induced CD30 expression on T cells of atopic asthmatics. Clin. Exp. Allergy 27 (1997) 780-786
16. Mahmoodi M., Khamesipour A., Dowlati Y., Rafati S., Momeni A.Z., Emamjomeh M., Hejazi H., and Modabber F. Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG. Clin. Exp. Immunol. 134 (2003) 303-308
17. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., and Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136 (1986) 2348-2357
18. Nakao K., Nagake Y., Okamoto A., Ichikawa H., Yamamura M., and Makino H. Serum levels of soluble CD26 and CD30 in patients on hemodialysis. Nephron 91 (2002) 215-221
19. Rogala B., Gluck J., and Mazur B. Do the molecules CD26 and lymphocytes activation gene-3 differentiate between type 1 and 2 T cell response?. J. Invest. Allergol. Clin. Immunol. 12 (2002) 198-203
20. Scheel-Toellner D., Richter E., Toellner K.M., Reiling N., Wacker H.H., Flad H.D., and Gerdes J. CD26 expression in leprosy and other granulomatous diseases correlate with the production of IFN-γ. Lab. Invest. 73 (1995) 685-690
21. Schonermarck U., Csernok E., Trabandt A., Hansen H., and Gross W.L. Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides. Clin. Exp. Rheumatol. 18 (2000) 457-463
22. Willheim M., Ebner C., Baier K., Kern W., Schrattbauer K., Thien R., Kraft D., Breiteneder H., Reinisch W., and Scheiner O. Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with Th1 subsets. J. Allergy Clin. Immunol. 100 (1997) 348-355
23. Yang S.S., Fu L.S., Chang C.S., Yeh H.Z., Chen G.H., and Kao J.H. Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C. J. Gastroenterol. Hepatol. 21 (2006) 1789-1793